Natixis Advisors LLC Has $2.03 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Natixis Advisors LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 109.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,850 shares of the biotechnology company’s stock after acquiring an additional 31,737 shares during the quarter. Natixis Advisors LLC’s holdings in Exelixis were worth $2,026,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after acquiring an additional 704,786 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Exelixis during the third quarter worth approximately $14,979,000. Raymond James Financial Inc. acquired a new position in Exelixis in the fourth quarter valued at approximately $17,046,000. Burney Co. bought a new position in Exelixis in the fourth quarter valued at approximately $12,267,000. Finally, Los Angeles Capital Management LLC grew its holdings in Exelixis by 20.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock worth $71,828,000 after acquiring an additional 366,141 shares during the period. 85.27% of the stock is owned by institutional investors.

Insider Buying and Selling at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the transaction, the chief financial officer now owns 779,607 shares in the company, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 in the last three months. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

NASDAQ EXEL opened at $37.72 on Tuesday. The stock has a market cap of $10.56 billion, a PE ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57. The firm has a 50-day moving average of $35.66 and a 200-day moving average of $33.00. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of analyst reports. Brookline Capital Management started coverage on Exelixis in a research note on Monday, December 23rd. They set a “buy” rating for the company. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Truist Financial boosted their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Guggenheim reissued a “buy” rating and set a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.